This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
== Measuring and processing the interferogram == The interferogram has to be measured from zero path difference to a maximum length that depends on the resolution required. In practice the scan can be on either side of zero resulting in a double-sided interferogram. Mechanical design limitations may mean that for the highest resolution the scan runs to the maximum OPD on one side of zero only. The interferogram is converted to a spectrum by Fourier transformation. This requires it to be stored in digital form as a series of values at equal intervals of the path difference between the two beams. To measure the path difference a laser beam is sent through the interferometer, generating a sinusoidal signal where the separation between successive maxima is equal to the wavelength of the laser (typically a 633 nm HeNe laser is used). This can trigger an analog-to-digital converter to measure the IR signal each time the laser signal passes through zero. Alternatively, the laser and IR signals can be measured synchronously at smaller intervals with the IR signal at points corresponding to the laser signal zero crossing being determined by interpolation. This approach allows the use of analog-to-digital converters that are more accurate and precise than converters that can be triggered, resulting in lower noise.
Americium (95Am) is an artificial element, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no known stable isotopes. The first isotope to be synthesized was 241Am in 1944. The artificial element decays by ejecting alpha particles. Americium has an atomic number of 95 (the number of protons in the nucleus of the americium atom). Despite 243Am being an order of magnitude longer lived than 241Am, the former is harder to obtain than the latter as more of it is present in spent nuclear fuel. Nineteen radioisotopes of americium, ranging from 229Am to 247Am have been characterized; another isotope, 223Am, has also been reported but is unconfirmed. The most stable isotopes are 243Am with a half-life of 7,350 years and 241Am with a half-life of 432.6 years. All of the remaining radioactive isotopes have half-lives that are less than seven days, the majority of which are shorter than two hours. This element also has fourteen meta states, with the most stable being 242m1Am (half-life 141 years). This isomer is unusual in that its half-life is far longer than that of the ground state of the same isotope.
== Career == Yates started working out properly in 1983 at Martin's Gym in the Temple Row area of Birmingham. During this time, he won the 1984 Mr. Birmingham and became the British Heavyweight Bodybuilding Champion for the first time in 1986. His professional record consists of 15 major contest wins and two second-place finishes, and he won every contest he entered from 1992 until his retirement in 1997. His career ended in large part due to injuries such as torn biceps and triceps, the latter occurring three weeks before his final contest at the 1997 Mr. Olympia, which he nevertheless won; his victory generated controversy, with many critics and fans alike believing the runner-up Nasser El Sonbaty deserved to win. He is one of only four men to retire as a reigning Mr. Olympia. Peter McGough gave Yates the nickname "The Shadow" for his tendency to unexpectedly appear at major bodybuilding contests and win, having neither confirmed nor denied whether he would compete beforehand, and for staying out of the public eye between contests. He is considered to be the first of the "mass monsters" in bodybuilding; he combined his enormous muscle mass along with peak conditioning, quoted as being "granite hardness". He believes his career-ending injuries were due to his habit of maintaining an extreme level of training intensity all year long, even when approaching contests and while cutting weight.
The island is known for using geothermal energy to provide electricity for its inhabitants. In San Carlos, Negros Occidental where energy company San Carlos Solar Energy (SaCaSol) is located, solar energy is being used to power the city and surrounding municipalities. Inland towns and cities of Negros uses hydroelectric power acquired from springs, rivers and waterfalls. Due to the island region's sugarcane-based agriculture, Negros may become the nation's major biofuel producer, with sugarcane being used for ethanol production.
Acute and chronic exposure also reduces glutathione reductase, an enzyme that catalyzes the reduction of glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), which is a critical molecule in resisting oxidative stress and maintaining the reducing environment of the cell.
Sources: en.wikipedia.org
Terry Peter Gallagher as Axel Zufo, a fossil fuels billionaire Billy Eichner as Waylen Lemming, a crypto billionaire David Pittu as Ronan Wylde, a banking billionaire Julie Halston as Kitty Munson, a multinational retail billionaire Matthew Laureano as Nate, a victim who is tortured and killed by the Assassin and Jeremy Rev Yolanda as Clara Gardner, a transgender scientist and Mike's best friend Lux Pascal as Clara after the transformation Laura Dreyfuss as Jennifer King Robert Harrington as Jefferson, Byron's bodyguard Kelli O'Hara as Juliana Williams, Meyer's wife Hazel Graye as Juliana after the transformation Kaylee Halko as Joey, the teenage daughter of Meyer and Juliana who has progeria Augusta Liv as Joey after the transformation Kevin Cahoon as Tiger "Tig" Forst, one of Byron and Franny's sons Ray Nicholson as Tig after the transformation Eric Petersen as Gunther Forst, one of Byron and Franny's sons Brandon Gillard as Gunther after the transformation Anthony Rapp as a Scientist who worked for the space colonization division of Byron's corporation Emma Halleen as Bella Grant, a school student who becomes fixated on the "Beauty" Annabelle Wachtel as Ruthie, Bella's best friend who is lamenting a failed nose job Paige McGarvin as Ruthie after the transformation Maria Dizzia as Marcy Grant, Bella's mother Daniel Stewart Sherman as Bella's father Carson Rowland as Conor, an employee of Byron's corporation who administers doses of the "Beauty" Ethan Eisenstein as Conor before the transformation Red Concepcion as Sir Ma'am, a social media influencer Sky Kawai as Sir Ma'am after the transformation
== L == lactalbumin - lactic acid - lactic acid autotroph - lactic fermentation - lagging strand - laminin - LDL receptor - Le Chatelier's principle - lectin - leucine - leucine-2-alanine enkephalin - leukotriene B4 receptor - LH - LH receptor - LHRH receptor - life - life form - ligand - light reactions - Lineweaver-Burk diagram - lipase - lipid - lipid anchored protein - lipid bilayer - lipoprotein - liquid - list of compounds - list of gene families - locus - luminescent protein - lymphocyte homing receptor - lysine - lysis - lysis buffer - lysozyme - lytic cycle
=== Driving === Methadone treatment may impair driving ability. Drug abusers had significantly more involvement in serious crashes than non-abusers in a study by the University of Queensland. In the study of a group of 220 drug abusers, most of them poly-drug abusers, 17 were involved in crashes killing people, compared with a control group of other people randomly selected having no involvement in fatal crashes. However, there have been multiple studies verifying the ability of methadone maintenance patients to drive. In the UK, persons who are prescribed oral methadone can continue to drive after they have satisfactorily completed an independent medical examination which will include a urine screen for drugs. The license will be issued for 12 months at a time and even then, only following a favourable assessment from their own doctor. Individuals who are prescribed methadone for either IV or IM administration cannot drive in the UK, mainly due to the increased sedation effects that this route of use can cause.
Capitalizing on the popularity of the Apollo space missions in the early 1970s, Pillsbury marketed "Food Sticks" (also known as "Space Food Sticks") for the consumer market. Fourteen individually packaged sticks were included in a box, and came in six flavors such as peanut butter, caramel, and chocolate. Food Sticks were marketed as a "nutritionally balanced between meal snack". Examples of derivative products can be found in NASA Space Center gift shops, general sweets and novelty shops, online retailers, or at Army Surplus stores. A popular example is freeze-dried ice cream. Tang, originally marketed in 1959, saw an increase in popularity in the 1960s due to its inclusion on American human space flights.
Sources: en.wikipedia.org
When it became evident that the police was incapable of containing the uprising, the South African Defence Force (SADF) was deployed to assist police operations – first in Joza township, outside Grahamstown, on 6 October, and then in Soweto the following morning. Radio Freedom welcomed the deployments as a sign of the apartheid regime's desperation, declaring, "There is no way out for the Botha regime... Botha’s guns and batons are failing." On 23 October, military repression accelerated in earnest with the launch of Operation Palmiet (Afrikaans for "bullrush") in Sebokeng and three nearby townships, Sharpeville, Boipatong, and Bophelong. As part of a campaign to "rid the area of criminal and revolutionary elements", a heavily armed joint force of 7,000 police and SADF members cordoned off the townships and conducted a house-to-house search of about 19,500 houses, accommodating an estimated 225,000 people. After being searched in their home and at roadblocks, residents were given labels or ink to wear to prove that they had been "vetted" and were allowed to move around. The labels bore the printed slogan, "I am your friend, trust me", while stamps on people's hands read "friendly forces". The Washington Post said that it was "the biggest crackdown on political dissent ever mounted" in South Africa, as well as the first time that the military had been "employed so openly to quell racial dissent".
In art, literature, and movies, dwarfs are rarely depicted as ordinary people who are very short but rather as a species apart. Novelists, artists, and moviemakers may attach special moral or aesthetic significance to their "apartness" or misshapenness. Artistic representations of dwarfism are found on Greek vases and other ancient artifacts, including ancient Egyptian art in which dwarfs are likely to have been seen as a divine manifestation, with records indicating that they were able to reach high positions in society at the time. The ancient Hindu text Bhagavata Purana devotes nine chapters to the legend of Vamana, the dwarf avatar of Vishnu.
== Distribution == The species is found in Central Asia, the Caucasus Mountains, and northeastern Africa. It can be found throughout the area of Afghanistan, Azerbaijan, Egypt, India, Iran, Iraq, Israel, Jordan, Kashmir, Libya, Palestine, Pakistan, Saudi Arabia, Sudan, the United Arab Emirates, Russia (adventive) and the United States (adventive).
== Chemical synthesis == Microbial catabolism of phytosterol side chains yields C-19 steroids, C-22 steroids, and 17-ketosteroids (i.e. precursors to adrenocortical hormones and contraceptives). The addition and modification of functional groups is key when producing the wide variety of medications available within this chemical classification. These modifications are performed using conventional organic synthesis and/or biotransformation techniques.
Carbohydrates are compounds made up of types of sugar. Carbohydrates are classified according to their number of sugar units: monosaccharides (such as glucose and fructose), disaccharides (such as sucrose and lactose), oligosaccharides, and polysaccharides (such as starch, glycogen, and cellulose). Proteins are organic compounds that consist of amino acids joined by peptide bonds. Since the body cannot manufacture some of the amino acids (termed essential amino acids), the diet must supply them. Through digestion, proteins are broken down by proteases back into free amino acids. Fats consist of a glycerin molecule with three fatty acids attached. Fatty acid molecules contain a -COOH group attached to unbranched hydrocarbon chains connected by single bonds alone (saturated fatty acids) or by both double and single bonds (unsaturated fatty acids). Fats are needed for construction and maintenance of cell membranes, to maintain a stable body temperature, and to sustain the health of skin and hair. Because the body does not manufacture certain fatty acids (termed essential fatty acids), they must be obtained through one's diet.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.